Alto Neuroscience, Inc. (NYSE:ANRO) Shares Bought by Rhumbline Advisers

Rhumbline Advisers raised its holdings in Alto Neuroscience, Inc. (NYSE:ANRO) by 24.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 25,556 shares of the company’s stock after purchasing an additional 5,008 shares during the period. Rhumbline Advisers owned about 0.09% of Alto Neuroscience worth $108,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the business. JPMorgan Chase & Co. raised its position in shares of Alto Neuroscience by 543.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,315 shares of the company’s stock valued at $278,000 after purchasing an additional 20,536 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Alto Neuroscience by 95.3% in the 3rd quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company’s stock valued at $13,965,000 after purchasing an additional 595,673 shares in the last quarter. Barclays PLC raised its position in shares of Alto Neuroscience by 872.7% in the 3rd quarter. Barclays PLC now owns 29,599 shares of the company’s stock valued at $339,000 after purchasing an additional 26,556 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Alto Neuroscience by 148.7% in the 3rd quarter. Geode Capital Management LLC now owns 469,988 shares of the company’s stock valued at $5,378,000 after purchasing an additional 281,018 shares in the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Alto Neuroscience in the 3rd quarter valued at approximately $124,000.

Analysts Set New Price Targets

Separately, Stifel Nicolaus dropped their price target on Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.75.

Alto Neuroscience Price Performance

Shares of ANRO opened at $3.35 on Tuesday. The stock has a fifty day moving average price of $3.88 and a 200 day moving average price of $6.64. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. Alto Neuroscience, Inc. has a 12 month low of $2.67 and a 12 month high of $18.35.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.